2020 Q1 Form 10-Q Financial Statement
#000156459020025197 Filed on May 14, 2020
Income Statement
| Concept | 2020 Q1 | 2019 Q1 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| YoY Change | ||
| Cost Of Revenue | ||
| YoY Change | ||
| Gross Profit | ||
| YoY Change | ||
| Gross Profit Margin | ||
| Selling, General & Admin | $34.26M | $18.90M |
| YoY Change | 81.27% | 135.96% |
| % of Gross Profit | ||
| Research & Development | $68.23M | $2.000M |
| YoY Change | 3311.25% | -94.09% |
| % of Gross Profit | ||
| Depreciation & Amortization | $110.0K | |
| YoY Change | 266.67% | |
| % of Gross Profit | ||
| Operating Expenses | $102.5M | $2.000M |
| YoY Change | 5024.35% | -95.22% |
| Operating Profit | -$102.5M | -$63.75M |
| YoY Change | 60.76% | |
| Interest Expense | $4.010M | $1.671M |
| YoY Change | 139.98% | -16810.0% |
| % of Operating Profit | ||
| Other Income/Expense, Net | -$1.595M | -$5.684M |
| YoY Change | -71.94% | 863.39% |
| Pretax Income | -$104.1M | -$69.44M |
| YoY Change | 49.88% | 63.66% |
| Income Tax | $0.00 | |
| % Of Pretax Income | ||
| Net Earnings | -$104.1M | -$69.44M |
| YoY Change | 49.9% | 52.44% |
| Net Earnings / Revenue | ||
| Basic Earnings Per Share | ||
| Diluted Earnings Per Share | -$779.7K | -$532.1K |
| COMMON SHARES | ||
| Basic Shares Outstanding | 123.8M | |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2020 Q1 | 2019 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $905.2M | $373.0M |
| YoY Change | 142.68% | |
| Cash & Equivalents | $757.0M | $373.0M |
| Short-Term Investments | $148.1M | |
| Other Short-Term Assets | $19.80M | $9.500M |
| YoY Change | 108.42% | |
| Inventory | ||
| Prepaid Expenses | ||
| Receivables | ||
| Other Receivables | ||
| Total Short-Term Assets | $925.0M | $382.5M |
| YoY Change | 141.83% | |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $24.60M | $1.900M |
| YoY Change | 1194.74% | |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | $23.20M | $12.50M |
| YoY Change | 85.6% | |
| Other Assets | $17.00M | $4.600M |
| YoY Change | 269.57% | |
| Total Long-Term Assets | $64.80M | $18.90M |
| YoY Change | 242.86% | |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $925.0M | $382.5M |
| Total Long-Term Assets | $64.80M | $18.90M |
| Total Assets | $989.8M | $401.4M |
| YoY Change | 146.59% | |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $13.10M | $12.30M |
| YoY Change | 6.5% | |
| Accrued Expenses | $48.30M | $18.60M |
| YoY Change | 159.68% | |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $64.90M | $35.50M |
| YoY Change | 82.82% | |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $461.3M | $54.90M |
| YoY Change | 740.26% | |
| Other Long-Term Liabilities | $11.50M | $400.0K |
| YoY Change | 2775.0% | |
| Total Long-Term Liabilities | $472.8M | $55.30M |
| YoY Change | 754.97% | |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $64.90M | $35.50M |
| Total Long-Term Liabilities | $472.8M | $55.30M |
| Total Liabilities | $609.1M | $149.2M |
| YoY Change | 308.24% | |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$240.6M | |
| YoY Change | ||
| Common Stock | $492.8M | |
| YoY Change | ||
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | $75.00M | |
| YoY Change | ||
| Treasury Stock Shares | $2.415M | |
| Shareholders Equity | $380.7M | $252.1M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $989.8M | $401.4M |
| YoY Change | 146.59% |
Cashflow Statement
| Concept | 2020 Q1 | 2019 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$104.1M | -$69.44M |
| YoY Change | 49.9% | 52.44% |
| Depreciation, Depletion And Amortization | $110.0K | |
| YoY Change | 266.67% | |
| Cash From Operating Activities | -$83.92M | -$59.14M |
| YoY Change | 41.9% | 229.47% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $4.477M | $427.0K |
| YoY Change | 948.48% | -102.81% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $42.50M | |
| YoY Change | ||
| Cash From Investing Activities | $38.02M | -$2.427M |
| YoY Change | -1666.67% | -84.01% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | $997.0K | |
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | $75.00M | |
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 439.2M | -1.651M |
| YoY Change | -26700.42% | -110.52% |
| NET CHANGE | ||
| Cash From Operating Activities | -83.92M | -59.14M |
| Cash From Investing Activities | 38.02M | -2.427M |
| Cash From Financing Activities | 439.2M | -1.651M |
| Net Change In Cash | 393.3M | -63.22M |
| YoY Change | -722.09% | 262.49% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$83.92M | -$59.14M |
| Capital Expenditures | $4.477M | $427.0K |
| Free Cash Flow | -$88.40M | -$59.57M |
| YoY Change | 48.4% | 2050.43% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2019Q4 | bbio |
Leo Call Option Liability Current
LEOCallOptionLiabilityCurrent
|
4078000 | |
| CY2019Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
3020000 | |
| CY2019Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
3527000 | |
| CY2019Q4 | us-gaap |
Liabilities
Liabilities
|
155703000 | |
| CY2019Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2019Q4 | us-gaap |
Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
|
2243000 | |
| CY2019Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2019Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
124000 | |
| CY2019Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
848107000 | |
| CY2019Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
254000 | |
| CY2019Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-440031000 | |
| CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
408454000 | |
| CY2019Q4 | us-gaap |
Minority Interest
MinorityInterest
|
65279000 | |
| CY2019Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
473733000 | |
| CY2019Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
631679000 | |
| CY2019Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2019Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
25000000 | |
| CY2019Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2019Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2019Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2019Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
500000000 | |
| CY2019Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
123658287 | |
| CY2020Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
121359855 | |
| CY2020Q1 | us-gaap |
Treasury Stock Shares
TreasuryStockShares
|
2414681 | |
| CY2020Q1 | us-gaap |
Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
|
us-gaap:LicenseMember | |
| CY2019Q1 | us-gaap |
Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
|
us-gaap:LicenseMember | |
| CY2019Q4 | bbio |
Build To Suit Lease Obligation Current
BuildToSuitLeaseObligationCurrent
|
8000000 | |
| CY2020Q1 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
2510000 | |
| CY2020Q1 | bbio |
Convertible Senior Notes
ConvertibleSeniorNotes
|
368923000 | |
| CY2020Q1 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
8678000 | |
| CY2020Q1 | us-gaap |
Treasury Stock Value
TreasuryStockValue
|
75000000 | |
| CY2020Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
123774536 | |
| CY2019Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
123658287 | |
| CY2020Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
102487000 | |
| CY2020Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-102487000 | |
| CY2019Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-63752000 | |
| CY2020Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
1941000 | |
| CY2019Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
2107000 | |
| CY2020Q1 | us-gaap |
Interest Expense
InterestExpense
|
4010000 | |
| CY2019Q1 | us-gaap |
Interest Expense
InterestExpense
|
1671000 | |
| CY2019Q1 | us-gaap |
Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
|
-4599000 | |
| CY2020Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
474000 | |
| CY2019Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-1521000 | |
| CY2020Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-1595000 | |
| CY2019Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-5684000 | |
| CY2020Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-104082000 | |
| CY2019Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-69436000 | |
| CY2020Q1 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
-12232000 | |
| CY2019Q1 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
-8251000 | |
| CY2020Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-91850000 | |
| CY2019Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-61185000 | |
| CY2020Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.78 | |
| CY2019Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.66 | |
| CY2020Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
117803438 | |
| CY2019Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
92330072 | |
| CY2020Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
472000 | |
| CY2020Q1 | us-gaap |
Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
|
-103610000 | |
| CY2019Q1 | us-gaap |
Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
|
-69436000 | |
| CY2020Q1 | us-gaap |
Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
|
-12232000 | |
| CY2019Q1 | us-gaap |
Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
|
-8251000 | |
| CY2020Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-91378000 | |
| CY2019Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-61185000 | |
| CY2020Q1 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
529000 | |
| CY2020Q1 | us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
|
8063000 | |
| CY2020Q1 | us-gaap |
Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments
|
167726000 | |
| CY2020Q1 | bbio |
Adjustments To Additional Paid In Capital Purchase Of Capped Calls
AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCalls
|
-49280000 | |
| CY2020Q1 | us-gaap |
Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
|
75000000 | |
| CY2020Q1 | bbio |
Issuance Repurchase Of Noncontrolling Interest
IssuanceRepurchaseOfNoncontrollingInterest
|
26565000 | |
| CY2020Q1 | us-gaap |
Minority Interest Period Increase Decrease
MinorityInterestPeriodIncreaseDecrease
|
-574000 | |
| CY2020Q1 | bbio |
Net Income Loss Excluding Redeemable Noncontrolling Interests Net Income Loss
NetIncomeLossExcludingRedeemableNoncontrollingInterestsNetIncomeLoss
|
-103216000 | |
| CY2018Q4 | us-gaap |
Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
|
122000 | |
| CY2018Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
377240000 | |
| CY2019Q1 | bbio |
Stock Issued During Repayment Of Nonrecourse Notes
StockIssuedDuringRepaymentOfNonrecourseNotes
|
179000 | |
| CY2019Q1 | bbio |
Issuance Repurchase Of Noncontrolling Interest
IssuanceRepurchaseOfNoncontrollingInterest
|
1320000 | |
| CY2019Q1 | bbio |
Temporary Equity Transfer To From Noncontrolling Interest
TemporaryEquityTransferToFromNoncontrollingInterest
|
870000 | |
| CY2019Q1 | us-gaap |
Minority Interest Period Increase Decrease
MinorityInterestPeriodIncreaseDecrease
|
-870000 | |
| CY2019Q1 | us-gaap |
Temporary Equity Net Income
TemporaryEquityNetIncome
|
-790000 | |
| CY2019Q1 | bbio |
Net Income Loss Excluding Redeemable Noncontrolling Interests Net Income Loss
NetIncomeLossExcludingRedeemableNoncontrollingInterestsNetIncomeLoss
|
-68646000 | |
| CY2019Q1 | us-gaap |
Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
|
202000 | |
| CY2019Q1 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
310459000 | |
| CY2020Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
10222000 | |
| CY2019Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
2232000 | |
| CY2020Q1 | us-gaap |
Accretion Expense
AccretionExpense
|
1761000 | |
| CY2019Q1 | us-gaap |
Accretion Expense
AccretionExpense
|
354000 | |
| CY2019Q1 | us-gaap |
Research And Development In Process
ResearchAndDevelopmentInProcess
|
2000000 | |
| CY2020Q1 | bbio |
Call Option Expense Income
CallOptionExpenseIncome
|
-539000 | |
| CY2019Q1 | bbio |
Call Option Expense Income
CallOptionExpenseIncome
|
1514000 | |
| CY2020Q1 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-1034000 | |
| CY2019Q1 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-339000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-2846000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
309000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
734000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
4234000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-1952000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
|
-7670000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
|
-432000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
1852000 | |
| CY2020Q1 | bbio |
Increase Decrease In Accrued Research And Development Liabilities
IncreaseDecreaseInAccruedResearchAndDevelopmentLiabilities
|
8626000 | |
| CY2019Q1 | bbio |
Increase Decrease In Accrued Research And Development Liabilities
IncreaseDecreaseInAccruedResearchAndDevelopmentLiabilities
|
1710000 | |
| CY2020Q1 | bbio |
Increase Decrease In Accrued Professional Services
IncreaseDecreaseInAccruedProfessionalServices
|
923000 | |
| CY2019Q1 | bbio |
Increase Decrease In Accrued Professional Services
IncreaseDecreaseInAccruedProfessionalServices
|
1370000 | |
| CY2020Q1 | bbio |
Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
|
-556000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
15000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
723000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-83920000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-59140000 | |
| CY2020Q1 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
42500000 | |
| CY2019Q1 | us-gaap |
Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
|
2000000 | |
| CY2020Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
4477000 | |
| CY2019Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
427000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
38023000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-2427000 | |
| CY2020Q1 | us-gaap |
Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
|
550000000 | |
| CY2020Q1 | us-gaap |
Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
|
12375000 | |
| CY2020Q1 | bbio |
Purchase Of Capped Calls
PurchaseOfCappedCalls
|
49280000 | |
| CY2020Q1 | us-gaap |
Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
|
75000000 | |
| CY2019Q1 | us-gaap |
Proceeds From Repayments Of Secured Debt
ProceedsFromRepaymentsOfSecuredDebt
|
179000 | |
| CY2020Q1 | us-gaap |
Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
|
24094000 | |
| CY2020Q1 | bbio |
Proceeds From Issuance Of Redeemable Convertible Noncontrolling Interests To Third Party Investors
ProceedsFromIssuanceOfRedeemableConvertibleNoncontrollingInterestsToThirdPartyInvestors
|
1000000 | |
| CY2019Q1 | us-gaap |
Payments Of Dividends
PaymentsOfDividends
|
997000 | |
| CY2019Q1 | us-gaap |
Payments Of Financing Costs
PaymentsOfFinancingCosts
|
936000 | |
| CY2020Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
734000 | |
| CY2019Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
103000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
439173000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-1651000 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
393276000 | |
| CY2019Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-63218000 | |
| CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
364197000 | |
| CY2018Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
436245000 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
757473000 | |
| CY2019Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
373027000 | |
| CY2020Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
2054000 | |
| CY2019Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
1176000 | |
| CY2020Q1 | us-gaap |
Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
|
664000 | |
| CY2020Q1 | bbio |
Recognition Of Property And Equipment Previously Classified In Other Assets
RecognitionOfPropertyAndEquipmentPreviouslyClassifiedInOtherAssets
|
10000000 | |
| CY2020Q1 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
9395000 | |
| CY2020Q1 | bbio |
Noncash Or Part Noncash Investing Transfer From To Noncontrolling Interest
NoncashOrPartNoncashInvestingTransferFromToNoncontrollingInterest
|
11601000 | |
| CY2019Q1 | bbio |
Noncash Or Part Noncash Investing Transfer From To Noncontrolling Interest
NoncashOrPartNoncashInvestingTransferFromToNoncontrollingInterest
|
-2968000 | |
| CY2019Q4 | bbio |
Fair Value Liabilities Transfers Between Level One Level Two Or Level Three Amount
FairValueLiabilitiesTransfersBetweenLevelOneLevelTwoOrLevelThreeAmount
|
0 | |
| CY2020Q1 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td> <td valign="top"> <p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="OrganizationandDescription"></a><a name="N1_ORGANIZATION_DESCRIPTION_BUSINESS"></a><font style="font-weight:normal;"><a name="OrganizationandDescription"></a></font><a name="N1_ORGANIZATION_DESCRIPTION_BUSINESS"></a>Organization and Description of Business </p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BridgeBio Pharma, Inc. (“BridgeBio”) was established to identify and advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. BridgeBio’s pipeline of programs spans early discovery to late-stage development. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 1, 2019, BridgeBio completed the 2019 Reorganization and closed the Initial Public Offering (“IPO”) of its common stock (see Note 13).<font style="font-size:12pt;"> </font>Since inception, BridgeBio has either created wholly-owned subsidiaries or has made investments in certain controlled entities, including partially-owned subsidiaries for which BridgeBio has a majority voting interest, and variable interest entities (“VIEs”) for which BridgeBio is the primary beneficiary (collectively, “we”, “our”, “us”). Our condensed consolidated financial statements include the accounts of our majority-owned affiliate, Eidos Therapeutics, Inc. (“Eidos”), which completed an IPO in June 2018. BridgeBio is headquartered in Palo Alto, California. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The results of operations and cash flows prior to the IPO closing on July 1, 2019 relate to BridgeBio Pharma LLC (“BBP LLC”), its subsidiaries and controlled entities. Subsequent to the IPO closing, the information relates to BridgeBio, its subsidiaries and controlled entities. All share and per share amounts in these condensed consolidated financial statements and related notes have been retroactively adjusted, where applicable, for the comparable periods presented to give effect to the exchange ratio applied in connection with the 2019 Reorganization. </p> | |
| CY2020Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include, but are not limited to, fair value of the liability component of our 2.50% convertible senior notes due 2027 (the “2027 Notes”, see Note 9), the fair value of the LEO Call Option liability (see Note 7), the present value of lease payments of our leases on lease commencement date, the valuation of our stock-based awards, accruals for certain employees’ performance-based milestones, accruals for research and development activities, accruals for contingent milestone payments in our license agreements and income tax uncertainties. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable. Actual results may differ from those estimates or assumptions. </p> | |
| CY2020Q1 | us-gaap |
Derivatives Embedded Derivatives
DerivativesEmbeddedDerivatives
|
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Capped Call Transactions </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, in connection with the issuance of the 2027 Notes <font style="color:#000000;">(see Note 9)</font>, BridgeBio entered into Capped Call Transactions. The Capped Call Transactions are expected generally to reduce the potential dilution to the holders of BridgeBio’s common stock upon any conversion of the 2027 Notes and/or offset any cash payments BridgeBio is required to make in excess of the principal amount of converted 2027 Notes, with such reduction and/or offset subject to a cap based on the cap price (see Note 9). The capped calls meet the conditions outlined in Accounting Standards Codification (“ASC”) 815-40, <font style="font-style:italic;">Derivatives and Hedging</font>, to be classified in stockholders’ equity as a reduction to additional paid-in capital and are not subsequently remeasured as long as the conditions for equity classification continue to be met.</p> | |
| CY2020Q1 | bbio |
Cash Cash Equivalents And Restricted Cash Maturity Period
CashCashEquivalentsAndRestrictedCashMaturityPeriod
|
P90D | |
| CY2019Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
373027000 | |
| CY2020Q1 | us-gaap |
Restricted Cash
RestrictedCash
|
424000 | |
| CY2020Q1 | bbio |
Fair Value Assets Transfers Between Level One Level Two Or Level Three Amount
FairValueAssetsTransfersBetweenLevelOneLevelTwoOrLevelThreeAmount
|
0 | |
| CY2019Q4 | bbio |
Fair Value Assets Transfers Between Level One Level Two Or Level Three Amount
FairValueAssetsTransfersBetweenLevelOneLevelTwoOrLevelThreeAmount
|
0 | |
| CY2020Q1 | bbio |
Fair Value Liabilities Transfers Between Level One Level Two Or Level Three Amount
FairValueLiabilitiesTransfersBetweenLevelOneLevelTwoOrLevelThreeAmount
|
0 | |
| CY2020Q1 | bbio |
Securities Collateral By Deposits Percentage Maintained By Third Party Custodian
SecuritiesCollateralByDepositsPercentageMaintainedByThirdPartyCustodian
|
1.02 | |
| CY2020Q1 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
841525000 | |
| CY2020Q1 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
792000 | |
| CY2020Q1 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
66000 | |
| CY2020Q1 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
842251000 | |
| CY2019Q4 | us-gaap |
Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
|
307736000 | |
| CY2019Q4 | us-gaap |
Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
|
307736000 | |
| CY2019Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
520846000 | |
| CY2019Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
254000 | |
| CY2019Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
521100000 | |
| CY2020Q1 | us-gaap |
Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
|
0 | |
| CY2020Q1 | bbio |
Short Term Marketable Securities Contractual Maturities
ShortTermMarketableSecuritiesContractualMaturities
|
P7M | |
| CY2020Q1 | bbio |
Long Term Marketable Securities Contractual Maturities
LongTermMarketableSecuritiesContractualMaturities
|
P14M | |
| CY2019Q1 | bbio |
Adjustments Of Carrying Value Of Noncontrolling Interest Additional Paid In Capital
AdjustmentsOfCarryingValueOfNoncontrollingInterestAdditionalPaidInCapital
|
-3000000 | |
| CY2020Q1 | us-gaap |
Noncontrolling Interest Increase From Subsidiary Equity Issuance
NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
|
26565000 | |
| CY2020Q1 | bbio |
Transfers To From Non Controlling Interest
TransfersToFromNonControllingInterest
|
-12175000 | |
| CY2020Q1 | us-gaap |
Net Income Loss Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossAttributableToNonredeemableNoncontrollingInterest
|
-11366000 | |
| CY2020Q1 | bbio |
Potential Milestone Compensation
PotentialMilestoneCompensation
|
23600000 | |
| CY2020Q1 | us-gaap |
Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
|
0 | |
| CY2020Q1 | bbio |
Accrued Termination Charges
AccruedTerminationCharges
|
0 | |
| CY2019Q4 | bbio |
Accrued Termination Charges
AccruedTerminationCharges
|
0 | |
| CY2020Q1 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P6Y1M6D | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
|
true | |
| CY2020Q1 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.062 | |
| CY2020Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
700000 | |
| CY2020Q1 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
694000 | |
| CY2020Q1 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
159000 | |
| CY2020Q1 | us-gaap |
Lease Cost
LeaseCost
|
853000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
2340000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
2724000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
1902000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
1485000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
|
1224000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
|
3798000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
13473000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
2285000 | |
| CY2020Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
11188000 | |
| CY2019Q4 | us-gaap |
Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
|
2811000 | |
| CY2019Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
|
2515000 | |
| CY2019Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
|
1812000 | |
| CY2019Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
|
1485000 | |
| CY2019Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
|
1272000 | |
| CY2019Q4 | us-gaap |
Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
|
1816000 | |
| CY2019Q4 | us-gaap |
Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
|
11711000 | |
| CY2019Q4 | bbio |
One Time Fees Receivable Noncurrent
OneTimeFeesReceivableNoncurrent
|
10000000 | |
| CY2019Q4 | us-gaap |
Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
|
us-gaap:AssetsNoncurrent | |
| CY2020Q1 | bbio |
Payable Related To Manufacturing Suite
PayableRelatedToManufacturingSuite
|
4000000 | |
| CY2019Q1 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2019Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
92000 | |
| CY2019Q1 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
492678000 | |
| CY2019Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-240629000 | |
| CY2019Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
252141000 | |
| CY2019Q1 | us-gaap |
Minority Interest
MinorityInterest
|
58318000 | |
| CY2020Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
10222000 | |
| CY2019Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2232000 | |
| CY2020Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
23130938 | |
| CY2019Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
7423752 |
